Ascendis Pharma AS (ASND) revenue breakdown
By region, USA is the largest at 76% of fiscal 2025 revenue; Europe grew fastest, 503% a year over 3 years.
Revenue by region
Fiscal years, as Ascendis Pharma AS reports them in its 10-K filings; fiscal 2025 total $720M.
| Regions | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| USA | $3M | $3M | $7M | $44M | $192M | $233M | $546M | 76% |
| Europe | — | — | — | $552,000 | $869,000 | $123M | $121M | 17% |
| Rest of World | $11M | $4M | $922,000 | $6M | $74M | $7M | $53M | 7% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ASND.
Open ASND in InvestinglyQuestions
Where does Ascendis Pharma AS make its money?
In fiscal 2025, by region: USA $546M, Europe $121M, Rest of World $53M.
From Ascendis Pharma AS's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.